Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock

NCT04020263 is registered in ClinicalTrials.gov with Pr Bruno LEVY as lead sponsor.

NCT NCT04020263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04020263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock
Lead sponsor
Pr Bruno LEVY
Phase
Phase 3
Overall status
Recruiting
Start date
July 3, 2023
Completion date
January 3, 2028
Enrollment
610 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

cardiogenic shock